PGR and breast cancer: The median percentage of participants at stages I–II was 84.0% (range 58.4–89.1%), based on seven studies, while the median percentage of participants who had estrogen- and/or progesterone-receptor-positive BC was 62.9% (range 20.0–83.9%), based on six studies.